Investors of Alexion Pharmaceuticals (ALXN) have voted in favor of the company’s acquisition by AstraZeneca. Pending regulatory approvals, the transaction is expected to close in Q3 2021.    Alexion Pharmaceuticals CEO Ludwig Hanston, Ph.D., said, “We are very pleased with today’s affirmative shareholder vote, which brings us one step closer to completing a transaction that will accelerate the combined company’s ability to develop and provide access to life-changing medicines for patients with rare and devastating diseases around the world.” (See Alexion stock analysis on TipRanks) The addition of Alexion is expected to strengthen AstraZeneca’s revenue profile and will be immediately accretive to its core earnings.
https://www.tipranks.com/news/alexion-investors-approve-acquisition-by-astrazeneca
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Alexion Pharmaceuticals Charts.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Alexion Pharmaceuticals Charts.